| Document |
Document Title |
|
JP2010524996A |
The present invention relates to the combination of the progesterone-receptor antagonist 11beta-(4-acetylphenyl)-17beta-hydroxy-17alpha-(1,1,2,2,2-pe
ntafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or ana...
|
|
JP4509380B2 |
A process for the preparation of a compound of the formulawherein the substituents are defined as in the specification.
|
|
JP4490560B2 |
|
|
JP2010521423A |
Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting...
|
|
JP4490116B2 |
The process for making steroid crystals having a predetermined average particle size of from 1 mum to 25 mum and a maximum particle size that does not exceed a predetermined maximum value of 100 mum, includes subjecting a supersaturated ...
|
|
JP4481660B2 |
Estrone derivatives (I) are new. Estrone derivatives of formula (I) and their stereoisomers, hydrates, salts or ester are new. [Image] X 1, X 2H or (CH 2) mCH(COOH)(CH 2) nR 1; R 11-7C haloalkyl; R aOH; and R b2-5C alkynyl; or CR aR b= C...
|
|
JP4471653B2 |
This invention relates to steroidal compounds having the formula I wherein: R1 is O, (H,H), (H,OH), NOH, whereby OH is optionally etherified or esterified; R2 and R3 are independently hydrogen or (C1-4) alkyl and at least one of R2 and R...
|
|
JP2010511729A |
The present invention comprises a composition and method treating eye diseases using a composition having a therapeutically effective amount of a progestagen and a pharmaceutically acceptable carrier, wherein the composition is applied t...
|
|
JP2010077157A |
To provide a new medicinal composition containing antiprogestin.The method and use for preventing and treating prostate diseases, in particular prostate cancer and benign prostate hyperplasia, in male mammals by the antiprogestin, in par...
|
|
JP2010509212A |
The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.
|
|
JP2010506867A |
The use of estradiol valerate (I) or 17beta -estradiol (I') in combination with 17alpha -cyanomethyl-17beta -hydroxy-estra-4,9-dien-3-one (dienogest) (II) is claimed in the production of a single- or multiphase combination preparation fo...
|
|
JP4417838B2 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
JP2010501505A |
Methods of deoxofluorination of ketones for the production of geminal difluoride compounds on an industrial scale include the following steps: -Preparing an exhaust mixture consisting of ketones and dialkylaminosulfatrifluorides;-At leas...
|
|
JP4399044B2 |
Percutaneous sorbefacients comprising hexylene glycol and 1-menthol, more particularly, percutaneous sorbefacients for female hormones or derivatives thereof; and preparations for percutaneous absorption which comprise a styrene/isoprene...
|
|
JP2010500323A |
The invention provides the use of a glucocorticoid receptor antagonist for the manufacture of a medicament for immune stimulation, such as prevention or treatment of infections or infectious conditions, in an aging mammalian subject, a m...
|
|
JP4382735B2 |
The present invention provides a therapeutic agent for neuropathic pain having an excellent treating effect on neuropathic pain, which is an intractable disorder. More specifically, the present invention provides a therapeutic agent for ...
|
|
JP4376055B2 |
The present invention provides a composition comprising (i) a compound comprising a sulphamate group ("a sulphamate compound"); and (ii) an apoptosis inducer.
|
|
JP4361976B2 |
The invention relates to a method for the preparation of a mixture of sulfated estrogens containing delta(8,9)-dehydro estrone Ädelta(8,9)DHEÜ or derivatives thereof.
|
|
JP4339591B2 |
The invention relates to 11beta-halogen steroids with general formula (I), whereby R11 is halogen, X-Y-Z represents a group with one of the two structures CH-C-C or CH2-C-C and the other radicals have the meaning that is indicated in the...
|
|
JP4335525B2 |
The invention relates to the use of progesterone receptor inhibitors for inhibition of growth-factor-dependency of tumor cells.
|
|
JP4335820B2 |
17alpha -Alkyl-11beta -halo-17beta -oxy-estratriene derivatives (I), having a 7alpha -side-chain, are new. 17alpha -Alkyl-11beta -halo-17beta -oxy-estratriene derivatives of formula (I), their acid addition salts and esters are new. [Ima...
|
|
JP4331478B2 |
The invention relates to a process for the production of 4-(17alpha-methyl-substituted 3-oxoestra-4,9-dien-11beta-yl)benzaldehyde-(1E or 1Z)-oximes of general formula (I), in which R1 is a hydrogen atom, a C1-6-alkyl radical or a CnF2n+1...
|
|
JP2009532338A |
Compounds of the formula, A—L—B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific memb...
|
|
JP4324249B2 |
This invention describes the new 17alpha-fluoroalkyl steroids of general formula I as well as their physiologically compatible salts with bases. The new compounds have an extraordinary strong antigestagenic action and are suitable for th...
|
|
JP4309661B2 |
A compound of formula (I): Each of R1, R2, R3, R4, R4', R5, R6, R7, R11, R12, R15, R16, and R17, independently, is hydrogen, halo, alkyl, haloalkyl, hydroxy, amino, carboxyl, oxo, sulfonic acid, or alkyl that is optionally inserted with ...
|
|
JP4302783B2 |
The invention relates to a tablet, capsule, or granule for oral administration comprising desogestrel wherein desogestrel is mixed or dissolved in a solid selected from a lubricant free from organic solvents, and a waxy substance not bei...
|
|
JP4297994B2 |
6-Hydroxy and 6-oxo-androstane derivatives having the general formula (I): wherein the symbol @ represents a single or a double bond and A, R<1> and R<2> have the meanings given in the description; a pharmaceutical composition comprising...
|
|
JP2009143925A |
To provide a method for treatment of a patient with hypertriglyceridemia, particularly a patient with low HDL cholesterol level and/or obesity.The method for treatment includes an administration of a compound shown by a formula (wherein ...
|
|
JP2009102412A |
To provide a method for administering a glucocorticoid receptor-specific antagonist to treat a patient diagnosed as stress disorder.The present invention provides a method for improving a stress disorder symptom in a patient having a nor...
|
|
JP4263478B2 |
The invention relates to a method for the production of 4-(17alpha substituted 3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R1-H, C1-6 alkyl or a CnF2n+1 group; R2-C1-4 alkyl, X=E- or Z-OH; an...
|
|
JP2009517426A |
Sulfamoyl compounds (I) of 8beta -substituted estratrienes and their pharmaceutically acceptable salts are new. Sulfamoyl compounds, of formula STEROID-Z (I), of 8beta -substituted estratrienes and their pharmaceutically acceptable salts...
|
|
JP2009515828A |
The disclosure provides androsterone derivatives. The derivatives of the disclosure are useful in the treatment of androgen- and estrogen-associated diseases and disorders, including breast cancer.
|
|
JP2009514807A |
Amphoteric compounds are described, having a zwitterionic structure of the betainic type having general formula (I) and their use for the control of phytopathogen fungi and/or the mitigation of abiotic and biotic stress.
|
|
JP2009513527A |
The invention pertains to steroid modified solatrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified solatrioses.
|
|
JP2009051858A |
To provide a method and a composition for remitting the symptom and condition relating to psychosis.This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which i...
|
|
JP4233504B2 |
The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalce...
|
|
JP2009501729A |
Methods and compositions for treating and/or preventing complications of preterm birth are provided. The methods involve administration of 2-methoxyestradiol, or an analog thereof, to a subject. Also provided are methods for diagnosing o...
|
|
JP4213205B2 |
The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the gro...
|
|
JP4212115B2 |
A matrix type transdermal patch for coadministering estradiol and another steroid wherein the matrix is composed of a N-vinyl-2-pyrrolidone-containing acrylic copolymer pressure sensitive adhesive, estradiol, the other steroid, and optio...
|
|
JP2008543935A |
The subject invention provides for new regimens for contraceptive dosage forms.
|
|
JP2008280355A |
To provide a new 8-substituted estratriene represented by general formula (I) that has in vitro a higher affinity to estrogen receptor preparation of rat prostate than to estrogen receptor preparation of rat uterus, and/or a pronounced e...
|
|
JP2008538753A |
The present invention relates to a transdermal hydroalcoholic testosterone gel formulation and a method for treating, preventing, or reducing the risk of developing deterioration of bone. The present invention also relates to a method fo...
|
|
JP2008266149A |
To establish a method for synthesizing a 13C-labeled aromatic compound such as 13C-labeled benzene from 13CH4 or 13CO2 concentrated at a different content rate of a carbon stable isomer from a naturally existing rate as a starting raw ma...
|
|
JP2004507511A5 |
|
|
JP4152431B2 |
Menses regulation and, when desired, contraception is achieved at low doses of estrogen and progestin, which otherwise would create episodes of breakthrough bleeding and/or withdrawal amenorrhea, by periodically inducing menses with an a...
|
|
JP4146897B2 |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula I wherein: -A-A- represents the group -CHR4-CHR5- or CR4-CR5- R3, R4 and R5 are ...
|
|
JP4145350B2 |
The invention relates to a 3 alpha -hydroxy, 17-(un)substituted derivatives of the androstane series and 3 alpha -hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at the recently identif...
|
|
JP4134304B2 |
|
|
JP4116080B2 |
This invention describes the new 7alpha-(5-methylaminopentyl)-estratrienes of general formula Iin whichR2 stands for a hydrogen or fluorine atom,R17 stands for a hydrogen atom, a methyl or ethinyl group,n stands for 2, 3 or 4, andx stand...
|
|
JP4097697B2 |
PCT No. PCT/EP96/04506 Sec. 371 Date Apr. 20, 1998 Sec. 102(e) Date Apr. 20, 1998 PCT Filed Oct. 17, 1996 PCT Pub. No. WO97/14696 PCT Pub. Date Apr. 24, 1997Compounds of the general formula Ia and Ib are described in which R1 and R2 are ...
|
